Skip to content

The Goldilocks Genome

A Medical Thriller

Elizabeth Reed Aden PhD
Barcode 9781684632541
Paperback

Sold out
Original price £14.35 - Original price £14.35
Original price
£14.35
£14.35 - £14.35
Current price £14.35

Click here to join our rewards scheme and earn points on this purchase!

Availability:
Out of stock

Release Date: 21/05/2024

Genre: Fiction
Sub-Genre: Crime Thrillers & Mystery
Label: SparkPress
Language: English
Publisher: She Writes Press

A Medical Thriller
The suicide of a woman being treated for depression initiates a cascade of events leading to a rash of unexplained deaths. When FDA epidemiologist Carrie Hediger inadvertently uncovers these deaths, she’s left with pressing questions: Are these deaths connected? What do they have in common? Are more deaths to come? Carrie and her team buck the system to find the answer.
When San Francisco–based FDA epidemiologist Dr. Carrie Hediger uncovers a rash of unexplained deaths while investigating the suspiciously convenient death of her best friend, she becomes determined to find answers—even if it leads her to a murderer, and even if confronting authority, using her wiles, and bending the rules to get justice risks her future in the FDA.

To unravel the puzzle, Carrie assembles a team: some talented post-doctoral fellows, a quirky pharmacologist, an unctuous chemist, and a skeptical FBI agent that she can’t help her attraction for. Together, they follow the data through the twists and turns, eventually uncovering that the Goldilocks effect in prescription drugs—the premise that people are inclined to seek “just the right amount” of something—is central to understanding these mysterious deaths. Through the twists and turns, Carrie and her team enter a race to uncover the truth . and catch a killer.

Grounded in real data analysis techniques, real science and pharmacology, and actual current psychiatric practices, The Goldilocks Genome is simultaneously a taut, race-against-time thriller and a condemnation of the psychiatric industry’s failure to implement genetic-based “personalized medicine”—a problem that persists to this day.